menu
    • menu
    [{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$800.0 million","upfrontCash":"$10.0 million","newsHeadline":"BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Seed Therapeutics","amount2":0.80000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"Seed Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Seed Thera.."},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at \u0153Targeted Protein Degradation Think Tank\u009d Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ST-00937","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Seed Thera.."},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$1,500.0 million","newsHeadline":"SEED Therapeutics Enters Collaboration with Eisai for Novel Molecular Glue Degraders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Seed Therapeutics","amount2":1.5,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seed Therapeutics \/ Eisai","highestDevelopmentStatusID":null,"companyTruncated":"Seed Thera.."}]

    Find Clinical Drug Pipeline Developments & Deals by Seed Therapeutics

    Menu

    Seed Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Seed Therapeutics

                            U.S.A arrow
                            Pharmaconex 2024
                            Not Confirmed

                            Seed Therapeutics

                            U.S.A arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Partner/Sponsor/Collaborator : Eisai

                            Deal Size : $1,500.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SEED Therapeutics Enters Collaboration with Eisai for Novel Molecular Glue Degraders

                            Details : The SEED-Eisai Research Collaboration leverages Eisai’s expertise to advance the SEED early-stage product RBM39 for treating neurodegeneration and cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $1,500.0 million

                            August 06, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Partner/Sponsor/Collaborator : Eisai

                            Deal Size : $1,500.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Seed Therapeutics

                            U.S.A arrow
                            Pharmaconex 2024
                            Not Confirmed

                            Seed Therapeutics

                            U.S.A arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ST-00937

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at œTargeted Protein De...

                            Details : ST-00937, a new chemical entity (NCE) molecular glue that has already achieved IND Candidate status and will be advanced for the treatment of cancers in SEED’s first IND filing, as early as 2024.

                            Product Name : ST-00937

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 26, 2023

                            Lead Product(s) : ST-00937

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Seed Therapeutics

                            U.S.A arrow
                            Pharmaconex 2024
                            Not Confirmed

                            Seed Therapeutics

                            U.S.A arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Partner/Sponsor/Collaborator : Eli Lilly

                            Deal Size : $800.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement...

                            Details : The collaboration aims to discover and develop new chemical entities (NCEs) that could produce therapeutic benefit through targeted protein degradation (TPD).

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : $10.0 million

                            November 13, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Partner/Sponsor/Collaborator : Eli Lilly

                            Deal Size : $800.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth